YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for YOLT-101, an in vivo base editing therapy targeting PCSK9 for the treatment of heterozygous familial hypercholesterolemia (HeFH).
“The FDA IND clearance marks a significant milestone for YolTech,” said Dr. Yuxuan Wu, Co-founder and CEO of YolTech Therapeutics. “In vivo gene editing represents a new generation of therapeutics—offering one-time, durable solutions for chronic and genetic diseases. We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases. ”